BRAF and colorectal carcinoma: For these considerations, IHC expression of PD1, PDL1, and BRAF proteins evaluation before therapy may help to determine patients that will benefit from immunotherapy and could be used as a base to design novel combination therapy (immunotherapy and BRAF inhibitors) for CRC.